A Phase 2 interventional study of Pemetrexed and Cisplatin in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 7 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 173rd largest by enrollment of the 223 interventional ones that give a count, is one of 8 that started in 2010, is one of 128 in phase 2, and was the 105th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 129th largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2010, is one of 73 in phase 2, and was the 87th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to assess how well the combination of pemetrexed with cisplatin can reduce tumor size.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pemetrexed · Drug: Cisplatin · Drug: Folic Acid · Drug: Vitamin B12 · Drug: Dexamethasone
500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
Also known as: Alimta, LY231514
75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
Administered orally.
Administered Intramuscular injection.
Administered orally.
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size \[\<10 millimeter (mm) short axis\]. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameters. ORR calculated as: (sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.
Time frame: From study enrollment until disease progression or recurrence up to completion of 3 cycles (21-day cycles) of chemotherapy
Percentage of Participants With No Viable Tumor Cells in Resected Lung Tissue [Pathological Complete Remission (pCR)]
pCR after the participant has undergone surgery was calculated as: (total number of participants with pCR) divided by (the total number of participants in pathological response population) multiplied by 100.
Time frame: At the time of surgery (within 3 to 6 weeks of Day 1 of Cycle 3 [21-day cycles] of chemotherapy)
Percentage of Participants Who Exhibit a Downward Shift in Tumor Extent From Stage IIIAN2 to Stages IIIA, II, I, or Stage 0
Tumor downstaging compared to baseline (Stage IIIAN2) were those participants who exhibited a downward shift in tumor extent from Stage IIIAN2 to Stages IIIA, II, I, or 0 were reported. Downstaging was based on radiological examination. Stage IIIAN2 was locally advanced and/or involved lymph nodes, metastasis in ipsilateral mediastinal and or subcarinal lymph nodes, tumors were ≤2 centimeters (cm) up to 5 cm in greatest dimension; Stage IIIA was locally advanced and/or involved lymph nodes, tumor extension was restricted to the affected lung; Stage II was locally advanced and/or involved lymph nodes; Stage I was small localized cancers, usually curable; Stage 0 the cancer did not spread beyond the inner lining of the lung. Missing responses were also reported. Percentage of participants calculated as: (number of participants with a downward shift in extent of their tumor) divided by (total number of evaluable participants) multiplied by 100.
Time frame: From study enrollment until disease progression or recurrence up to completion of 3 cycles (21-day cycles) of chemotherapy
Overall Survival (OS)
OS was defined as duration from the date of study enrollment to the date of death from any cause. Participants not known to have died as of the data inclusion cut-off date were censored at the date of last contact. The last contact for participants in post-discontinuation was the last date participant was known to be alive.
Time frame: Enrollment until the date of death from any cause up to 64 months
Progression-Free Survival (PFS)
PFS was defined as the time from date of first dose to the first observation of disease progression or death due to any cause. For participants not known to have died or did not have objective progressive disease (PD) as of the data inclusion cut-off date, PFS was censored at the date of the last objective progression-free disease assessment. PD was defined using RECIST v1.1 criteria as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
Time frame: Enrollment until the first date of objectively determined PD or death up to 64 months
| Milestone | Pemetrexed + Cisplatin |
|---|---|
| Started | 19 |
| ≥1 dose chemo | 19 |
| ≥1 dose chemo, baseline, cy 3 assessment | 17 |
| 3 cycles of chemo, then surgery | 15 |
| Completed | 18 |
| Not completed | 1 |
| Withdrew: Death | 1 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size \[\<10 millimeter (mm) short axis\]. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameters. ORR calculated as: (sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.
| percentage of participants | Pemetrexed + Cisplatin |
|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] | 41.2 (18.4 to 67.1) |
pCR after the participant has undergone surgery was calculated as: (total number of participants with pCR) divided by (the total number of participants in pathological response population) multiplied by 100.
| percentage of participants | Pemetrexed + Cisplatin |
|---|---|
| Percentage of Participants With No Viable Tumor Cells in Resected Lung Tissue [Pathological Complete Remission (pCR)] | 93.3 (68.1 to 99.8) |
Tumor downstaging compared to baseline (Stage IIIAN2) were those participants who exhibited a downward shift in tumor extent from Stage IIIAN2 to Stages IIIA, II, I, or 0 were reported. Downstaging was based on radiological examination. Stage IIIAN2 was locally advanced and/or involved lymph nodes, metastasis in ipsilateral mediastinal and or subcarinal lymph nodes, tumors were ≤2 centimeters (cm) up to 5 cm in greatest dimension; Stage IIIA was locally advanced and/or involved lymph nodes, tumor extension was restricted to the affected lung; Stage II was locally advanced and/or involved lymph nodes; Stage I was small localized cancers, usually curable; Stage 0 the cancer did not spread beyond the inner lining of the lung. Missing responses were also reported. Percentage of participants calculated as: (number of participants with a downward shift in extent of their tumor) divided by (total number of evaluable participants) multiplied by 100.
| percentage of participants | Pemetrexed + Cisplatin |
|---|---|
| No Change or Worsening of Tumor Stage | 29.4 (10.3 to 56.0) |
| Change to Stage IIIA | 29.4 (10.3 to 56.0) |
| Change to Stage II | 11.8 (1.5 to 36.4) |
| Change to Stage I | 17.6 (3.8 to 43.4) |
| Missing | 11.8 (1.5 to 36.4) |
OS was defined as duration from the date of study enrollment to the date of death from any cause. Participants not known to have died as of the data inclusion cut-off date were censored at the date of last contact. The last contact for participants in post-discontinuation was the last date participant was known to be alive.
| months | Pemetrexed + Cisplatin |
|---|---|
| Overall Survival (OS) | 34.6 (10.8 to NA) |
PFS was defined as the time from date of first dose to the first observation of disease progression or death due to any cause. For participants not known to have died or did not have objective progressive disease (PD) as of the data inclusion cut-off date, PFS was censored at the date of the last objective progression-free disease assessment. PD was defined using RECIST v1.1 criteria as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
| months | Pemetrexed + Cisplatin |
|---|---|
| Progression-Free Survival (PFS) | 12.4 (7.0 to 21.7) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Cisplatin | — | 2/19 (10.5%) | 15/19 (78.9%) |
| Event | Pemetrexed + Cisplatin |
|---|---|
| Acute abdomenGastrointestinal disorders | 1/19 |
| Paraneoplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/19 |
| Event | Pemetrexed + Cisplatin |
|---|---|
| NauseaGastrointestinal disorders | 4/19 |
| FatigueGeneral disorders | 4/19 |
| Neutrophil count decreasedInvestigations | 4/19 |
| StomatitisGastrointestinal disorders | 3/19 |
| AstheniaGeneral disorders | 3/19 |
| PyrexiaGeneral disorders | 3/19 |
| HypotensionVascular disorders | 3/19 |
| AnaemiaBlood and lymphatic system disorders | 2/19 |
| ConstipationGastrointestinal disorders | 2/19 |
| Platelet count decreasedInvestigations | 2/19 |
All participants who received at least 1 dose of chemotherapy.
| Age, Continuous(years) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 62.5 ± 9.32 |
| Sex: Female, Male(Participants) | Pemetrexed + Cisplatin |
|---|---|
| Female | 6 |
| Male | 13 |
| Race/Ethnicity, Customized(participants) | Pemetrexed + Cisplatin |
|---|---|
| White | 19 |
| Region of Enrollment(participants) | Pemetrexed + Cisplatin |
|---|---|
| Italy | 19 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Pemetrexed + Cisplatin |
|---|---|
| 0 | 15 |
| 1 | 4 |
| Initial Pathological Diagnosis(participants) | Pemetrexed + Cisplatin |
|---|---|
| Adenocarcinoma, Lung | 17 |
| Carcinoma, Large Cell, Lung | 1 |
| Carcinoma, Non-Small Cell, Lung | 1 |
| Tumor-Node-Metastasis (TNM) Stage of Disease(participants) | Pemetrexed + Cisplatin |
|---|---|
| T1aN2M0 | 3 |
| T1bN2M0 | 2 |
| T2aN2M0 | 3 |
| T2bN2M0 | 3 |
| T3N2M0 | 8 |
| Tobacco Consumption Status(participants) | Pemetrexed + Cisplatin |
|---|---|
| Current Tobacco User | 4 |
| Former Tobacco User | 12 |
| Never Used Tobacco | 3 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of Nov 2010, a primary completion of Jul 2013 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin
Carcinoma, Non-Small-Cell Lung →